Lavie Bio announces commercial expansion of Yalos™ to winter wheat

Winter wheat is one of the crucial crops North America and globally, contributing significantly to the agricultural economy and food supply. The United States is expected to produce about 1.28 billion bushels in 2024(1), with a market value, according to Biography of Lavie estimate, between $5–10 billion dollars The introduction of Yalos™ in this market offers considerable potential to capture market share by improving crop productivity and sustainability. To date, Biography of Lavie focused on the spring wheat market, as well as durum wheat and barley, which together form a smaller market compared to winter wheat.

In field trials, Yalos™ demonstrated improved early vigor, biomass, root and shoot development, nutrient availability and feed quality in winter wheat. Yalos™ aims to reduce crop abandonment rates and increase farm productivity through advanced biological technologies.

Furthermore, Biography of Lavie plans to expand Yalos™ to other key crops, such as soybeans and canola, with field trials underway North America and a commercial launch planned for 2025. The size of the US soybean market is estimated by Biography of Lavie around $56.2 billion in 2024.

“We are excited to bring Yalos™ to winter wheat growers,” said Amit NoamCEO of Biography of Lavie. “Yalos™ addresses key growing challenges and improves plant health and yield. Our strategy is to continually bring new, innovative agrobiological products to market, while expanding existing products to more crops and regions. This expansion is part of our plan for Yalos™ to become a leading solution for growers of all major field crops, reinforcing our commitment to advancing agricultural productivity and sustainability globally.”

(1) https://www.nass.usda.gov/Newsroom/2024/05-10-2024.php

About Lavie Bio Ltd.

Biography of Laviea subsidiary of Evogene Ltd., aims to improve food quality, sustainability and agricultural productivity through the introduction of microbiome-based agrobiological products. Biography of Lavie uses a proprietary predictive computing platform, the BDD Platform, powered by Evogene’s proprietary MicroBoost AI technology engine, harnessing the power of big data, artificial intelligence and advanced computing, for the discovery, optimization and development of bio-stimulant and bio-pesticide products.

For more information, visit www.lavie-bio.com

About Evogene Ltd.

Evogene (Nasdaq: EVGN) (TASE: EVGN) is a computational biology company focused on revolutionizing the development of life science products by using cutting-edge technologies to increase the probability of success while reducing the time and cost of development. Evogene has developed three unique technology drivers: MicroBoost AI, ChemPass AI and GeneRator AI – leveraging Big Data and Artificial Intelligence and integrating a deep multidisciplinary understanding of life sciences. Each technology engine is focused on the discovery and development of products based on one of the following building blocks: microbes (MicroBoost AI), small molecules (ChemPass AI), and genetic elements (AI GeneRator). Evogene uses its technology engines to develop products through subsidiaries and strategic partners. Currently, Evogene’s principal subsidiaries are using the technology engines to develop human microbiome-based therapies through Biomica Ltd., agricultural chemicals through AgPlenus Ltd. and agricultural biologics through Lavie Bio Ltd.

For more information, please visit: www.evogene.com

Forward-Looking Statements

This press release contains “forward-looking statements” about future events. These statements can be identified by words such as “may,” “could,” “expect,” “hope,” “intend,” “anticipate,” “plan,” “believe,” “plan,” “estimate,” “demonstrate” or words of similar meaning. For example, Evogene and its subsidiaries use forward-looking statements in this press release when discussing the ability of Yalos™ to capture market share in winter wheat, the ability of Yalos™ to reduce crop abandonment rates and increase agricultural productivity, the expansion of Yalos™ into other key crops, such as soybeans and canola, Biography of Lavie entry into new markets for organic products, in particular Brazil And EuropeThese statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties that are difficult to predict and are not guarantees of future performance. Consequently, the actual future results, performance or achievements of Evogene and its subsidiaries may differ materially from what is expressed or implied by these forward-looking statements as a result of various factors, many of which are beyond the control of Evogene and its subsidiaries, including, without limitation, the current war between IsraelHamas and Hezbollah and any worsening of the situation Israel Potential risks include, but are not limited to, further mobilizations or escalation on Israel’s northern border, as well as the risk factors contained in Evogene’s reports filed with the relevant regulatory authority. In addition, Evogene and its subsidiaries rely, and expect to continue to rely, on third parties to conduct certain activities, such as their field trials and preclinical studies, and if such third parties fail to successfully perform their contractual obligations, comply with regulatory requirements or meet anticipated deadlines, Evogene and its subsidiaries could experience significant delays in conducting their activities. Evogene and its subsidiaries disclaim any obligation or undertaking to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions.

Investor Relations Contact:
Rachel Pomerantz Gerber I am responsible for investor relations at Evogene.
(protected email) I Tel: +972-8-9311901

Logo: https://mma.prnewswire.com/media/1947468/Evogene.jpg
Logo: https://mma.prnewswire.com/media/945133/lavie_bio_Logo.jpg

SOURCE Biography of Lavie